2002 TARGET TERM TRUST INC
NSAR-A, EX-27, 2000-07-31
Previous: 2002 TARGET TERM TRUST INC, NSAR-A, 2000-07-31
Next: ANTEX BIOLOGICS INC, 8-K, 2000-07-31


WARNING: THE EDGAR SYSTEM ENCOUNTERED ERROR(S) WHILE PROCESSING THIS SCHEDULE.

<TABLE> <S> <C>

<ARTICLE> 6
<CIK> 0000893227
<NAME> 2002 TARGET TERM TRUST
<MULTIPLIER> 1000

<S>                             <C>
<PERIOD-TYPE>                   06-MOS
<FISCAL-YEAR-END>                          NOV-30-2000
<PERIOD-START>                             DEC-01-1999
<PERIOD-END>                               MAY-31-2000
<INVESTMENTS-AT-COST>                          122,436
<INVESTMENTS-AT-VALUE>                         118,739
<RECEIVABLES>                                    1,657
<ASSETS-OTHER>                                      28
<OTHER-ITEMS-ASSETS>                                 0
<TOTAL-ASSETS>                                 120,425
<PAYABLE-FOR-SECURITIES>                         7,717
<SENIOR-LONG-TERM-DEBT>                              0
<OTHER-ITEMS-LIABILITIES>                        2,509
<TOTAL-LIABILITIES>                             10,226
<SENIOR-EQUITY>                                      0
<PAID-IN-CAPITAL-COMMON>                       113,526
<SHARES-COMMON-STOCK>                            7,803
<SHARES-COMMON-PRIOR>                            7,803
<ACCUMULATED-NII-CURRENT>                        7,958
<OVERDISTRIBUTION-NII>                               0
<ACCUMULATED-NET-GAINS>                        (7,299)
<OVERDISTRIBUTION-GAINS>                             0
<ACCUM-APPREC-OR-DEPREC>                       (3,986)
<NET-ASSETS>                                   110,199
<DIVIDEND-INCOME>                                    0
<INTEREST-INCOME>                                4,250
<OTHER-INCOME>                                       0
<EXPENSES-NET>                                     940
<NET-INVESTMENT-INCOME>                          3,310
<REALIZED-GAINS-CURRENT>                         (782)
<APPREC-INCREASE-CURRENT>                      (1,671)
<NET-CHANGE-FROM-OPS>                              857
<EQUALIZATION>                                       0
<DISTRIBUTIONS-OF-INCOME>                      (3,361)
<DISTRIBUTIONS-OF-GAINS>                             0
<DISTRIBUTIONS-OTHER>                                0
<NUMBER-OF-SHARES-SOLD>                              0
<NUMBER-OF-SHARES-REDEEMED>                          0
<SHARES-REINVESTED>                                  0
<NET-CHANGE-IN-ASSETS>                         (2,504)
<ACCUMULATED-NII-PRIOR>                          8,010
<ACCUMULATED-GAINS-PRIOR>                      (6,517)
<OVERDISTRIB-NII-PRIOR>                              0
<OVERDIST-NET-GAINS-PRIOR>                           0
<GROSS-ADVISORY-FEES>                              390
<INTEREST-EXPENSE>                                 275
<GROSS-EXPENSE>                                  3,310
<AVERAGE-NET-ASSETS>                           111,491
<PER-SHARE-NAV-BEGIN>                            14.44
<PER-SHARE-NII>                                   0.42
<PER-SHARE-GAIN-APPREC>                         (0.31)
<PER-SHARE-DIVIDEND>                            (0.43)
<PER-SHARE-DISTRIBUTIONS>                            0
<RETURNS-OF-CAPITAL>                                 0
<PER-SHARE-NAV-END>                              14.12
<EXPENSE-RATIO>                                   1.69



</TABLE>


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission